All Dr Mariana Argenziano (Associate Director Manufacturing Technologies – Ncardia) articles
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
ArticleTime for change: non-human primates in drug research
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.